Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB1 | Q9H4B7 | 4/20 | 0.43 |
| ▸ | ACHE | P22303 | 2/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | GFER | P55789 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16137286 | 0.83 | ACHE (0.42) | TUBB1ACHEALDH1A1CYP3A4GAA | |
| SCHEMBL16071608 | 0.82 | ACHE (0.40) | TUBB1ACHEALDH1A1CYP3A4GAA | |
| SCHEMBL26359975 | 0.81 | TUBB1 (0.43) | TUBB1ACHETAAR1CYP3A4POLB | |
| SCHEMBL1245069 | 0.77 | ACHE (0.46) | TUBB1ACHETAAR1CYP3A4POLB | |
| SCHEMBL13401233 | 0.76 | TUBB1 (0.39) | TUBB1ACHETAAR1CYP3A4POLB | |
| SCHEMBL167017 | 0.76 | TUBB1 (0.41) | TUBB1ACHEALDH1A1CYP3A4LMNA | |
| SCHEMBL17087196 | 0.74 | ACHE (0.44) | TUBB1ACHETAAR1ALDH1A1CYP3A4 | |
| SCHEMBL14458264 | 0.73 | ACHE (0.54) | TUBB1ACHEALDH1A1CYP3A4POLB | |
| SCHEMBL16071615 | 0.73 | MAPT (0.36) | TUBB1ACHEALDH1A1CYP3A4POLB | |
| SCHEMBL16071633 | 0.73 | GAA (0.38) | TUBB1ACHEALDH1A1CYP3A4GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170360785-A1 | PYRIMIDINE FGFR4 INHIBITORS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2017-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170360785-A1 | PYRIMIDINE FGFR4 INHIBITORS | FGFR4, FGFR1, FGFR3 | TUBB1 1561/4885ACHE 4885/4885TAAR1 4455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.